Thermo Fisher Scientific Debt issued (Note 13) increased by 84.4% to $5.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 84.4%, from $2.84B to $5.24B.
High proceeds indicate active debt financing to support growth or liquidity, while low proceeds may suggest reliance on internal cash or limited market access.
Cash inflows received from the issuance of long-term debt instruments, such as bonds or bank loans. This metric reflects...
Standard financing activity metric across all capital-intensive industries.
other_proceeds_from_issuance_of_long_term_debt| Q2 '21 | Q3 '21 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $3.12B | $0.00 | $0.00 | $1.21B | -$1.00M | $0.00 | $2.84B | $5.24B |
| QoQ Change | — | — | -100.0% | — | — | -100.1% | +100.0% | — | +84.4% |
| YoY Change | — | — | — | — | — | — | — | +135.7% | +84.4% |